share_log

Trinity Biotech | 6-K: Report of foreign private issuer (related to financial reporting)

Trinity Biotech | 6-K: Report of foreign private issuer (related to financial reporting)

Trinity Biotech | 6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  2024/10/02 23:24

Moomoo AI 已提取核心信息

Trinity Biotech reported H1 2024 revenues of $30.5M, up 6.3% YoY, primarily driven by a 78.2% increase in Point-of-Care revenues to $7.6M following the commercial launch of TrinScreen HIV. Clinical laboratory product revenues declined 4.5% to $20.4M, while laboratory services decreased 17.1% to $2.6M.The company recorded an operating loss of $7.1M, improved from $18.8M loss in H1 2023, benefiting from lower impairment charges and reduced SG&A expenses. Gross margin remained stable at 36.8%. Financial expenses decreased to $3.1M from $6.4M YoY. The net loss was $10.1M ($1.10 per ADS), compared to $11.8M loss in H1 2023.In January 2024, Trinity secured an amended term loan with Perceptive, providing $22M additional funding, including $12.5M for CGM assets acquisition from Waveform. The loan terms improved with interest rate reduction to 8.75% plus SOFR. Cash position stood at $5.3M as of June 30, 2024, with management expressing confidence in continued operations for at least 12 months.
Trinity Biotech reported H1 2024 revenues of $30.5M, up 6.3% YoY, primarily driven by a 78.2% increase in Point-of-Care revenues to $7.6M following the commercial launch of TrinScreen HIV. Clinical laboratory product revenues declined 4.5% to $20.4M, while laboratory services decreased 17.1% to $2.6M.The company recorded an operating loss of $7.1M, improved from $18.8M loss in H1 2023, benefiting from lower impairment charges and reduced SG&A expenses. Gross margin remained stable at 36.8%. Financial expenses decreased to $3.1M from $6.4M YoY. The net loss was $10.1M ($1.10 per ADS), compared to $11.8M loss in H1 2023.In January 2024, Trinity secured an amended term loan with Perceptive, providing $22M additional funding, including $12.5M for CGM assets acquisition from Waveform. The loan terms improved with interest rate reduction to 8.75% plus SOFR. Cash position stood at $5.3M as of June 30, 2024, with management expressing confidence in continued operations for at least 12 months.
Trinity Biotech报告2024年上半年收入为3050万美元，同比增长6.3%，主要得益于TrinScreen HIV商业推出后，现场检测收入增加78.2%达到760万美元。临床实验室产品收入下降4.5%至2040万美元，而实验室服务减少17.1%至260万美元。公司记录经营亏损710万美元，较2023年上半年1880万美元的亏损有所改善，受益于减低的减值费用和降低的销售和管理费用。毛利率保持稳定在36.8%。财务费用同比减少至310万美元，之前为640万美元。净亏损为1010万美元（每股ADS 1.10美元），相比于2023年上半年1180万美元的亏损。在2024年1月，Trini...展开全部
Trinity Biotech报告2024年上半年收入为3050万美元，同比增长6.3%，主要得益于TrinScreen HIV商业推出后，现场检测收入增加78.2%达到760万美元。临床实验室产品收入下降4.5%至2040万美元，而实验室服务减少17.1%至260万美元。公司记录经营亏损710万美元，较2023年上半年1880万美元的亏损有所改善，受益于减低的减值费用和降低的销售和管理费用。毛利率保持稳定在36.8%。财务费用同比减少至310万美元，之前为640万美元。净亏损为1010万美元（每股ADS 1.10美元），相比于2023年上半年1180万美元的亏损。在2024年1月，Trinity与Perceptive达成了一项修订的定期贷款协议，提供2200万美元的额外资金，其中包括1250万美元用于从Waveform收购CGm资产。贷款条款得到改善，利率降低至8.75%加上SOFR。截至2024年6月30日，现金头寸为530万美元，管理层表示对至少12个月的持续运营充满信心。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    沃氪医疗
    WOK
    -- 0.570
    908 Devices
    MASS
    -- 4.480
    Vicarious Surgical
    RBOT
    -- 6.560
    Icecure Medical
    ICCM
    -- 1.176
    Apyx Medical
    APYX
    -- 1.370
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点